Please assess the completion status of the following clinical trial:

Trial Title: Maternal TDF and FTC to Reduce NNRTI Resistance Mutations After Intrapartum NVP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serologically confirmed HIV infection;~* Gestational age of 28 to 38 weeks;~* Previous selection of a NVP-based PMTCT regimen (with or without ZDV)~* Willingness to participate in a randomized trial;~* Willingness to follow up in a postpartum visit schedule;~* Willingness to allow her infant to participate in this trial;~Exclusion Criteria:~* Use of antiretroviral medications before this pregnancy, even in a single dose.~* Current use of antiretroviral medications for treatment of advanced HIV disease and/or AIDS~* Illness or complication of pregnancy likely to warrant transfer to the University Teaching Hospital (UTH), known at time of randomization;~* Known or suspected allergy to NVP or other benzodiazepine medications;~* History of known liver disease.~* Hemoglobin level of 7.9 g/dL or less

- Gender: FEMALE
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- combination tenofovir-emtricitabine (Type: EXPERIMENTAL): None
- control arm (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).